{"id":23,"date":"2026-07-14T18:10:15","date_gmt":"2026-07-14T18:10:15","guid":{"rendered":"https:\/\/blitzlab.eu\/blog-blitz-triple-g-kaufen\/"},"modified":"2026-10-23T23:36:58","modified_gmt":"2026-10-23T21:36:58","slug":"buy-blitz-triple-g","status":"publish","type":"page","link":"https:\/\/blitzlab.eu\/en\/blog-blitz-triple-g-kaufen\/","title":{"rendered":"Blitz Triple G kaufen \u2013 Forschungsleitfaden"},"content":{"rendered":"
\n
Home<\/a>\u203a<\/span>Blog<\/a>\u203a<\/span>Buy Blitz Triple G 2026<\/span><\/div>\n\n

Buy Blitz Triple G 2026 \u2014 Triple Agonist (GLP-1\/GIP\/Glucagon) for Metabolic Receptor Research (EU)<\/h1>\n

Peptide Research \u00b7 28 June 2026 \u00b7 12 min read \u00b7 Research Use Only<\/p>\n\n

\n In short:<\/strong> Blitz Triple G is a synthetic multi-target research peptide of GLP-1\/GIP\/Glucagon class<\/strong> (triple agonist). This research guide summarises what the published in-vitro and animal model literature<\/strong> documented for this peptide class \u2013 from receptor binding and cAMP response profiles to observations in adipocyte, hepatocyte, and pancreas cell models. At BlitzLab, as 10mg vial<\/strong> with batch-related Certificate of Analysis (COA)<\/a>, HPLC \u2265 99 %, EU delivery. Price: <\/strong>. For research use only (RUO).\n <\/div>\n
<\/svg> Scientific-factual research guide. Summarises published study observations. No health, dosage or application advice, no statement about suitability in humans. Research Use Only.<\/div>\n\n

Blitz Triple G at a glance<\/h2>\n \n
Designation<\/th>Blitz Triple G<\/td><\/tr>\n
Identity<\/th>Synthetic multi-target research peptide of the GLP-1\/GIP\/glucagon class (triple agonist)<\/td><\/tr>\n
Synonyms<\/th>Triple G, tri-target peptide<\/td><\/tr>\n
Research context<\/th>Receptor binding & cAMP response at GLP-1, GIP and glucagon receptors, receptor-pharmacological in-vitro\/cell models (in vitro\/animal model)<\/td><\/tr>\n
CAS number<\/th>See CoA (the batch-specific COA is authoritative)<\/span><\/td><\/tr>\n
Molecular formula<\/th>See CoA<\/td><\/tr>\n
Form<\/th>Lyophilised powder (freeze-dried), sealed vial<\/td><\/tr>\n
Amount<\/th>10 mg per vial<\/td><\/tr>\n
Purity<\/th>\u226599% (HPLC), identity confirmed by LC-MS<\/td><\/tr>\n
Analysis<\/th>External third-party laboratory, batch-specific COA<\/td><\/tr>\n
Intended use<\/th>For Research Use Only (RUO)<\/td><\/tr>\n
Price<\/th> \u00b7 Shipping from Germany<\/td><\/tr>\n <\/table>\n\n

What is Blitz Triple G?<\/h2>\n

Blitz Triple G is a synthetic multi-target research peptide<\/strong> the GLP-1\/GIP\/Glucagon class. As a so-called triple agonist, it belongs to a group of peptides that are being investigated in preclinical literature for three metabolically relevant receptors: the GLP-1 receptor<\/strong>, and GIP receptor<\/strong> and the Glucagon receptor<\/strong>. The substance is supplied as a stable lyophilisate in a sealed vial (10 mg) and is used in laboratory research as a defined reference substance for receptor pharmacology and cell biology study models. The CAS number and molecular formula are documented in the batch-specific certificate of analysis.<\/p>\n\n

Molecular profile & target structure<\/h2>\n

Triple agonists of this class are designed so that a single peptide sequence binds to three related receptors in the incretin and glucagon families. GLP-1, GIP and glucagon receptors are among the Class B G protein-coupled receptors (GPCRs)<\/strong> and are about the activation of adenylyl cyclase with the cAMP signalling pathway<\/strong> linked. In the research literature, Blitz Triple G therefore serves as a model system for investigating the parallel binding and signal response at multiple metabolic target receptors<\/strong> to characterise. The combination of a defined synthetic sequence and good analytical characterisation makes the peptide a frequently used reference in receptor and metabolic biology study models.<\/p>\n\n

What in-vitro and animal model studies document<\/h2>\n

The following summary reflects only what is described in the publicly accessible preclinical literature<\/strong> \u2013 it is not a statement about an effect or suitability in humans.<\/p>\n